One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end ...

Lauren, a 35-year-old wife and mother of three daughters, had just finished breastfeeding her youngest when she first noticed ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

Roche RHHBY announced positive data from the late-stage lidERA Breast Cancer study on pipeline candidate giredestrant.

This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...

Normally, HER2 helps your healthy breast cells grow and divide. But too much HER2 can trigger cells to grow out of control. HER2-positive breast cancer happens when the HER2 gene in your DNA mutates ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...